CA-CONVIVA
24.8.2022 16:03:10 CEST | Business Wire | Press release
Conviva , the leading global streaming analytics platform, has been recognized by the Association for Computing Machinery’s Special Interest Group on Data Communications (ACM SIGCOMM) with two prestigious innovation awards: the ACM SIGCOMM Test of Time Award and the SIGCOMM Networking Systems Award. Both awards honor the vision and impact of Conviva’s commitment to data and analytics technology innovation that began with the founding team of Hui Zhang, Aditya Ganjam, Jibin Zhan (Conviva) and Ion Stoica (Conviva, Databricks) defining standards that pushed the industry forward. This team’s work has continued to be foundational to enabling and continuously improving the quality and overall end-user experience that is industry standard in streaming media today. This same core technology has also proven applicable to virtually any industry where technology and business leaders have a business imperative to make the vast amount of their data available to their organizations in real time, and actionable across every aspect of their operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220824005274/en/
2022 SIGCOMM Test of Time Award
The 2022 ACM SIGCOMM Test of Time Award honors Conviva’s founders for their 2011 paper detailing the direct connection between video quality and user engagement. The annual award recognizes papers published 10 to 12 years in the past that are deemed to offer data, perspective and predictions that still have significance today.
“What we didn’t predict was who would be the winners and losers of the streaming wars,” said Hui Zhang, Conviva Cofounder, Chief Scientist and Chairman of the Board. “What we did know ten years ago, and still holds true today, is that measuring quality and engagement in streaming is core to market growth and who comes out on top. Having this real-time information at their fingertips is mission-critical for publishers and brands to inform any actions to optimize their services and maximize their investment.”
The breakthrough technology that underscored the Test of Time award was documented in a paper, “Understanding the Impact of Video Quality on User Engagement” that was first presented at the 2011 ACM SIGCOMM conference. Its authors were Conviva founders Hui Zhang, Ion Stoica, Aditya Ganjam and Jibin Zhan, along with teammates Florin Dobrian, Asad Awan, Dilip Joseph and Vyas Sekar, an academic collaborator and now Professor of Carnegie Mellon University. The paper pioneered large-scale video measurements and documented an in-depth study conducted on how video quality affects user engagement, which has had a lasting impact on the optimization of streaming media.
The State of Streaming
While video streaming quality has significantly improved in the past 10 years, consumer expectations have also risen to new heights. Nothing short of high resolution and smooth playback all-the-time is acceptable. Detection and identifying root-cause of any barriers to an excellent experience is more challenging than ever due to the complexity of today’s streaming technology ecosystem. Diverse mobile-connected TV devices and associated video/app tech stacks, sophisticated cloud-based media preparation, content distribution, and advertising tech stacks all can contribute to more microscopic and subtle failure modes. More than a trillion-dollar market (ranging from media, entertainment, sports, education and fitness industries) is built on top of streaming, making it table stakes to ensure every media consumer has the best experience.
Each quarter, Conviva conducts an in-depth global review of streaming quality and adoption in a report entitled The State of Streaming.
2022 SIGCOMM Networking Systems Award
A separate SIGCOMM award committee also selected Conviva as the recipient of the 2022 SIGCOMM Networking Systems Award, recognizing the development of a networking system that has had a significant impact on the world of communications and computer networks. According to the committee, Conviva was recognized for “the sustained impact that Conviva has had, from the earliest days of translating published research to a successful real-world system, making a significant impact on real-world streaming systems and CDNs and then continuing to give back to the research community via data sharing and publications.”
“While I am very proud that Conviva has been recognized for its impact on the industry, our contribution to the research community is also very meaningful,” added Zhang. “I am thankful to all of our academic collaborators and talented undergrad and graduate interns from top research programs at CMU, Berkeley, Chicago, Purdue, and USC.”
The 2022 Test of Time winners were selected by an esteemed committee of technology experts that included Fadel Adib (MIT), Venkat Padmanabhan (Microsoft Research India, chair), Jennifer Rexford (Princeton) and Renata Teixeira (Netflix). The 2022 SIGCOMM Networking Systems Award was selected by a committee that included Vishal Misra, Anees Shaikh and Puneet Sharma.
About ACM SIGCOMM
The Association for Computing Machinery (ACM) is the world’s largest educational and scientific computing society, and SIGCOMM is ACM’s professional forum for the discussion of topics in the field of communications and computer networks, including technical design and engineering, regulation and operations, and the social implications of computer networking. The SIG's members are particularly interested in the systems engineering and architectural questions of communication.
About Conviva
Conviva helps streaming businesses act within seconds of observation to grow their business ahead of the competition. Conviva’s leading global streaming analytics platform provides comprehensive, continuous, census-level measurement through real-time, server side sessionization at scale. Using just a single sensor and a single pipeline, its 60+ patent platform enables marketers, advertisers, tech ops, engineering and customer care teams to acquire, engage, monetize and retain their audiences. Conviva is dedicated to supporting brands like DAZN, Disney+, Hulu, Paramount+, Peacock, Sky, Sling TV, TED and WarnerMedia as they unlock the incredible opportunity in streaming media. Today the Conviva platform processes nearly 3 trillion streaming data events daily, supporting more than 500 million unique viewers watching 200 billion streams per year across 4 billion applications streaming on devices. To learn more, visit www.conviva.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220824005274/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom